Loading...

Gdpawel's Recent CancerCompass Activity

  • Gdpawel has replied to a post on the message board

    More information about HBOT for radiation-induced necrosis: http://cancerfocus.org/forum/showthread.php?t=1131 Treating radiation-induced necrosis with Avastin: http://cancerfocus.org/forum/showthread.php?t=3551

    April 12 at 10:23 PM view post
    • Gdpawel has commented on a news story

      Will the monoclonal antibody ever reach inside the "individual" cancer cell? It may be very important to zero in on different proteins. However, when actually taking the "targeted" drug, will it even enter the cancer cell? Once entered, does it immediately get metabolized or pumped out, or does it accumulate? In other words, will it work for every individual patient that tested positive for the target? Simply havin...

      March 17 at 10:06 PM view news story
      • Gdpawel has replied to a post on the message board

        Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab (Herceptin)E. M. Olson 1, M. Abdel-Rasoul 1, J. Maly 1, C. S. Wu 1, N. U. Lin 2, and C. L. Shapiro 1,1. Division of Medical Oncology, Department of Internal Medicine, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State U...

        March 16 at 7:37 PM view post
        • Gdpawel has created a new message board discussion

          During the past decade it has been frequently observed that patients with breast cancer treated with a taxane-containing chemotherapy regimen, either in the adjuvant setting or in the metastatic setting, presenting central nervous system (CNS) involvement as the only evidence of disease progression. More studies were therefore interested to evaluate the incidence of CNS metastases in patients with early and advanced ...

          March 16 at 7:35 PM view discussion
          • Gdpawel has changed their profile photo
            March 16 at 4:28 PM
            • Gdpawel has replied to a post on the message board

              Researchers have been focusing on the development of sensitive assays that allow the specific detection of single tumor cells or small amounts of cell-free tumor DNA in the peripheral blood of cancer patients (Annual Review of Medicine Vol. 63: 199-215). Quantification of circulating DNA by real-time PCR may be a good and simple tool for detection of cancer with a potential to clinical applicability together with oth...

              March 14 at 4:59 PM view post
              • Gdpawel has created a new message board discussion

                Circulating cell-free DNA carrying tumor-specific alterations (circulating tumor DNA) is more effective at monitoring metastatic breast cancer than current biomarkers approved by the US Food and Drug Administration and circulating tumor cells, according to a proof-of-concept study.The study, led by Sarah-Jane Dawson, PhD, from the University of Cambridge and the Cancer Research UK Cambridge Institute, in the United K...

                March 14 at 4:57 PM view discussion
                • Gdpawel has replied to a post on the message board

                  In 2006, Dr. Deborah Armstrong's study was published on this protocol and many doctors thought the results would change the field forever. It compared standard intravenous chemotherapy with intraperitoneal chemotherapy. The test regimen was highly toxic, and not all patients could tolerate it, with only 42% of women being able to finish the rather arduous trial. But Armstrong had the most definitive results. Why...

                  March 14 at 4:50 PM view post
                  • Gdpawel has replied to a post on the message board

                    Patients with advanced ovarian cancer who undergo intensive treatment with chemotherapy that bathes the abdomen are significantly more likely to live longer than those who receive standard intravenous (IV) chemotherapy, according to a study that analyzed long-term follow-up from two landmark Gynecologic Oncology Group (GOG) trials comprising 876 patients. Results of the study are being presented at the Society of Gyn...

                    March 14 at 4:48 PM view post
                    • Gdpawel has created a new message board discussion

                      Long-term results from 2 large studies confirm the superiority of intraperitoneal (IP) administration of chemotherapy over intravenous (IV) administration after surgery in patients with advanced ovarian cancer."We have known for some years that intraperitoneal administration may give superior results...but it is balanced by more toxicity," said Jubilee Brown, MD, associate professor of obstetrics and gynecology at th...

                      March 14 at 4:46 PM view discussion
                      Loading...
                      Load more activity
                      Loading more activity

                      About Gdpawel

                      Caregiver, Researcher
                      Ovarian Cancer
                      Cancer Treatments, Chemotherapy, Clinical Trials and Research, Conventional Treatments, Genetics, Radiation, Side Effects, Supplements, Surgery

                      I was a spouse/caregiver to an cancer patient. I became intensely interested in cancer medicine by virtue of working through, enduring and surviving my wife's illness. Although I had a college education, the experience helped me to gather knowledge by virtue of voluminous reading and hundreds of hours of past and "ongoing" personal communication with noted authorities and experts in the field. I still keep in touch with many of them (surgeons, medical and radiation oncologists). Although retired, privately, I've been a student of Cell Function Analysis. I do not have any financial conflicts of interest raising the awareness of this technology. On the internet, my point with respect to this systematic procedure is to educate patients and others that such techniques exist, and might be very valuable. To paraphrase Martin Luther King Jr: "A scientific communication should be judged on the quality of its content and only secondarily, or not at all, on the qualifications of its author." http://pathology2.jhu.edu/ovca/story.cfm?PersonID=33

                      We care about your feedback. Let us know how we can improve your CancerCompass experience.